Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Progression from oligoarticular to polyarticular psoriatic arthritis and apremilast as a disease modifier: Novel insights from FOREMOST.
Journal: Rheumatology (Oxford, England)
Published: February 09, 2026
Efficacy and Safety of Apremilast Over 52 Weeks in Patients with Plaque Psoriasis in High-Impact Areas and Impaired Quality of Life.
Journal: Dermatology and therapy
Published: December 06, 2024
Treatment of early oligoarticular psoriatic arthritis with apremilast: primary outcomes at week 16 from the FOREMOST randomised controlled trial.
Journal: Annals of the rheumatic diseases
Published: March 19, 2024
Microangiopathic thrombocytopenia caused by vitamin B12 deficiency responding to plasma exchange.
Journal: British journal of haematology
Published: March 19, 2024
Effect of apremilast on hand and whole-body MRI assessments of inflammation in patients with psoriatic arthritis (MOSAIC): a phase 4, multicentre, single-arm, open-label study.
Journal: The Lancet. Rheumatology
Published: December 22, 2023
Efficacy and safety of apremilast in patients with limited skin involvement, plaque psoriasis in special areas and impaired quality of life: Results from the EMBRACE randomized trial.
Journal: Journal of the European Academy of Dermatology and Venereology : JEADV
Published: June 29, 2022
Naldemedine versus placebo for opioid-induced constipation (COMPOSE-1 and COMPOSE-2): two multicentre, phase 3, double-blind, randomised, parallel-group trials.
Journal: The lancet. Gastroenterology & hepatology
Published: February 01, 2017
Showing 1-9 of 9
Last Updated: 09/26/2026